supp.fit

Manganese: study protocols

13 study groups say how much Manganese participants took a day. These are the doses the studies gave. They are not a recommendation.

Manganese: what the research found →

Dose per serving from products

8,990 products in our catalogue print how much Manganese a serving holds.

Most common: 1 mg to 2.5 mg, 39% of 8,990 products.

Dose per servingProducts
100 mcg or less
432
100 mcg to 250 mcg
439
250 mcg to 500 mcg
1,067
500 mcg to 1 mg
1,453
1 mg to 2.5 mg
3,506
2.5 mg to 5 mg
1,414
5 mg to 10 mg
449
over 10 mg
230

Dose per serving from research

13 study groups in 10 studies say how much Manganese participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 2.5 mg to 5 mg and 1 g to 2.5 g, 31% of 13 study groups each.

Daily doseStudy groups
2.5 mg or less
1
2.5 mg to 5 mg
4
5 mg to 10 mg
0
10 mg to 25 mg
0
25 mg to 50 mg
0
50 mg to 100 mg
0
100 mg to 250 mg
1
250 mg to 500 mg
1
500 mg to 1 g
2
1 g to 2.5 g
4

Commonly used together

8 of 13 study groups took Manganese with something else. Shown: what 3 or more different studies gave.

What was given together, not what works together.

Taken withStudy groups
Zinc
5
Copper
4
Vitamin C
3

13 study groups

Study
MRI of colorectal cancer liver metastases: comparison of orally administered manganese with intravenously administered gadobenate dimeglumine
2012 · CMC-001 (oral manganese-based contrast medium) · Adults aged 51–79 with 1–6 suspected colorectal cancer liver metastases referred for evaluation before partial liver resection
1.6 g1 day20
Lesion Visualization of an Oral Manganese Contrast Agent Compared to Unenhanced MRI and Gadobenate Dimeglumine in Patients Undergoing Liver Magnetic Resonance Imaging for Evaluation of Colorectal Cancer Metastases: Centralized Assessment of a Randomized, Crossover, Phase II Study
2025 · ACE-MBCA (oral manganese contrast agent) · Adults aged 51–79 years with known or suspected colorectal liver metastases
1.6 g1 day20
Efficacy of a combination of FCHG49 glucosamine hydrochloride, TRH122 low molecular weight sodium chondroitin sulfate and manganese ascorbate in the management of knee osteoarthritis
2000 · intervention group · Adults with knee osteoarthritis; age and sex not reported
304 mg26 weeks—
Spinal bone loss in postmenopausal women supplemented with calcium and trace minerals
1994 · trace minerals only · Healthy postmenopausal women, mean age 66 years
5 mg2 years—
The effects of antioxidant vitamin supplementation on expiratory flow rates at rest and during exercise
2015 · antioxidant vitamin supplementation (AVS) · healthy nonsmoking adults, 5 men and 5 women, consuming fewer than 5 servings of fruit and vegetables per day
2.5 mg4 weeks10
Glucosamine, chondroitin, and manganese ascorbate for degenerative joint disease of the knee or low back: a randomized, double-blind, placebo-controlled pilot study
1999 · combination therapy · male U.S. Navy diving and special warfare personnel with chronic pain and radiographic degenerative joint disease of the knee or low back
228 mg16 weeks—
[Vitrum osteomag in prevention of osteoporosis in postmenopausal women: results of the comparative open multicenter trial]
2004 · Group 1: Vitrum Osteomag · Postmenopausal women with osteopenia; age range not reported
3.6 mg1 year125
Spinal bone loss in postmenopausal women supplemented with calcium and trace minerals
1994 · calcium plus trace minerals · Healthy postmenopausal women, mean age 66 years
5 mg2 years—
Manganese-based oral contrast agent for liver magnetic resonance imaging: evaluation of the time course and dose response of liver signal intensity enhancement
2010 · 0.8 g MnCl2 group · Patients with liver metastases diagnosed by computed tomography
800 mg1 day11
Manganese-based oral contrast agent for liver magnetic resonance imaging: evaluation of the time course and dose response of liver signal intensity enhancement
2010 · 1.6 g MnCl2 group · Patients with liver metastases diagnosed by computed tomography
1.6 g1 day9
Oral manganese for liver imaging at three different field strengths
2004 · Half-strength CMC-001 · Healthy men, ages 20–39 years
800 mg1 day6
Oral manganese for liver imaging at three different field strengths
2004 · Full-strength CMC-001 · Healthy men, ages 20–39 years
1.6 g1 day6
Antioxidant micronutrients and biomarkers of oxidative stress and inflammation in colorectal adenoma patients: results from a randomized, controlled clinical trial
2010 · antioxidant micronutrient combination · Patients with a history of sporadic colorectal adenoma; age and sex not specified
5 mg120 days—